Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind140
Udgave nummer5
Sider (fra-til)445-450
Antal sider6
ISSN0006-4971
DOI
StatusUdgivet - 4 aug. 2022

Bibliografisk note

Copyright © 2022 American Society of Hematology.

ID: 78266006